โš ๏ธ Medical Notice: If you are experiencing a medical emergency, call 911 or go to the nearest ER. This directory is an educational resource and not an emergency medical service.
๐Ÿ›๏ธ Verified NIH Protocol โ€ข Sourced via U.S. National Library of Medicine (Last Synced: 2025-09-05)

Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study

๐ŸŸข Recruiting Protocol / Phase N/A โš™๏ธ Medical Device Protocol Sponsor: KidSIM Simulation Program

๐Ÿฉบ Protocol Summary

Aerosol Generating Medical Procedures (AGMP) are procedures that have the potential to create tiny particles suspended in the air. These particles can contain germs such as viruses. The Coronavirus Disease 2019 (COVID-19) pandemic was caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients infected with SARS-CoV-2 experience unusually high rates of critical illness that needs advanced airway management and intensive care unit admission. Bag-valve-mask (BVM) ventilation, endotracheal Intubation (ETI) and chest compressions are sometimes required for critically ill COVID-19 patients, and may contribute to a high risk of infection amongst Health Care Workers (HCW). To lessen HCW risk during high-risk procedures, a device called an aerosol box has been developed to place over the head of the patient, shielding the provider's face from virus droplets suspended in the air. The purpose of this research study is to better understand how particles disperse during AGMPs, more specifically during the provision of cardiopulmonary resuscitation (CPR). The project team hopes what is learned from the project can help inform infection control measures. This could help make changes to the clinical environment and make it safer for HCW's. The investigators intend to explore how an aerosol box performs in reducing contamination of HCW's who perform critical airway interventions during resuscitation events.

Primary Research Facility: Department of Emergency Medicine, Children's Hospital of Los Angeles (Los Angeles, California)

๐Ÿ“‹ Preliminary Self-Screener

0 of 3 Answered

Answer all 3 basic criteria below to see your preliminary screening result:

๐Ÿ“ Primary Site Map

Site: Department of Emergency Medicine, Children's Hospital of Los Angeles โ€” Los Angeles, California

๐Ÿ“ All Participating Trial Locations (4 Sites)

Multi-Center Trial

This protocol is enrolling participants across multiple clinical centers:

1. Department of Emergency Medicine, Children's Hospital of Los Angeles โ€” Los Angeles, California
2. KidSIM, Alberta Children's Hospital โ€” Calgary, Alberta โ€ข Contact: (403) 955-2633
3. Department of Pediatrics, The Hospital for Sick Children โ€” Toronto, Ontario
4. Department of Pediatrics, CHU Sainte-Justine โ€” Montreal, Quebec

๐Ÿ“„ Print Doctor Discussion Sheet

Preview and print a 1-page summary with 5 tailored questions for your physician.

๐Ÿ’ฐ Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act ยง 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

๐Ÿ’ก Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.

๐Ÿ›๏ธ Official Government Provenance

NIH ClinicalTrials.gov Protocol Record

NCT Identifier: NCT05868239 โ€ข Last Synced: 2025-09-05
View on ClinicalTrials.gov โ†—
๐Ÿ“ž Call Desk ๐Ÿ“‹ Check Eligibility